Engineered Toxin Body Technology

Molecular TemplatesEngineered Toxin Body Technology

The Engineered Toxin Bodies (ETBs) platform represents a new class of targeted biologic therapy with unique biological properties.


Engineered Toxin Bodies (ETBs) can induce internalization into cells even against non- or poorly internalizing targets can induce their own internalization.

Forced internalization expands the universe of extracellular receptors that can be targeted for direct cell-kill. MT-3724, the Company’s lead ETB program, induces rapid and efficient internalization of CD20.


ETBs work through a unique intracellular mechanism of action: enzymatic and permanent ribosome inactivation.

ETBs self-route to the cytosol and enzymatically and irreversibly depurinate ribosomes to shutdown protein synthesis. In vitro and clinical data have demonstrated that ETB activity is not inhibited by generalized mechanisms of chemo-resistance.


ETBs have been proprietarily de-immunized to reduce both adaptive and innate immune responses.

Reduction in adaptive immune recognition has resulted in dramatically diminished anti-drug antibody (ADA) responses in murine and non-human primate models. Reduction in innate immune recognition has resulted in improved safety in non-human primate models.


ETBs self-navigate to the cytosol. Payloads can be genetically or chemically conjugated to ETBs to allow for extracellular targeting and intracellular delivery. Payloads can include proteins, nucleic acids, or small molecules.

ETBs can deliver foreign class 1 antigens for processing and presentation in complex with MHC class I molecules on the surface of target cells. Seeding of foreign antigens in a tumor cell for surface expression is a novel approach to immuno-oncology.